Table 3 Univariate and multivariate analysis of CSS for patients with stage IIIA–N2 NSCLC

Age

3881

  < 65

1708

Reference

  ≥ 65

2173

1.46 (1.35–1.59)

 < 0.01

1.37 (1.26–1.49)

 < 0.01

Sex

3881

 Female

2132

Reference

 Male

1749

1.39 (1.28–1.50)

 < 0.01

1.37 (1.26–1.49)

 < 0.01

Year of diagnosis

3881

 2000–2009

1747

Reference

 2010–2019

2134

0.54 (0.50–0.59)

 < 0.01

0.56 (0.52–0.61)

 < 0.01

Race

3881

 White

3126

Reference

 Other

755

0.78 (0.70–0.86)

 < 0.01

0.81 (0.73–0.90)

 < 0.01

Primary site

3881

 Upper lobe

2421

Reference

 Middle lobe

202

1.01 (0.84–1.21)

0.92

1.17 (0.97–1.41)

0.10

 Lower lobe

1258

1.04 (0.95–1.13)

0.44

1.06 (0.97–1.160)

0.18

Laterality

3881

 Left

1764

Reference

 Right

2117

0.94 (0.87–1.02)

0.11

0.94 (0.88–1.02)

0.14

Histologic type

3881

 LUAD

2777

Reference

 LUSC

658

1.30 (1.17–1.45)

 < 0.01

1.17 (1.04–1.30)

0.01

 Large cell

114

1.34 (1.07–1.67)

0.01

1.25 (1.00–1.57)

0.05

 Other

332

1.01 (0.87–1.17)

0.91

1.00 (0.86–1.16)

0.99

T stage

3881

 T1

1532

Reference

 T2

2349

1.26 (1.16–1.37)

 < 0.01

1.260 (1.16–1.37)

 < 0.01

Surgery

3881

 Lobectomy

3259

Reference

 Sublobectomy

405

1.33 (1.17–1.50)

 < 0.01

1.45 (1.27–1.64)

 < 0.01

 Pneumonectomy

217

1.31 (1.12–1.53)

 < 0.01

0.95 (0.80–1.13)

0.55

Surg/Rad Seq

3881

 Non-PORT

2214

Reference

 PORT

1667

0.92 (0.85–1.01)

0.06

1.03 (0.94–1.12)

0.56

Chemotherapy

3881

 No

1180

Reference

 Yes

2701

0.61 (0.56–0.66)

 < 0.01

0.70 (0.64–0.77)

 < 0.01

Regional nodes positive

3881

  < 4

2505

Reference

  ≥ 4

1376

1.40 (1.29–1.51)

 < 0.01

1.51 (1.38–1.64)

 < 0.01